Pure Global AI
NCT05902377Recruiting

68Ga-NY104 PET/CT Imaging in Renal Cell Carcinoma

68Ga-NY104 PET/CT Imaging in Patients With Confirmed or Suspicious Renal Cell Carcinoma
Peking Union Medical College HospitalPhase 2ClinicalTrials.govdiagnostic test
Verified
Study focus
Disease/Condition
Renal Cell Carcinoma
Drug/Device/Intervention
68Ga-NY104 PET/CT
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Peking Union Medical College Hospital
Location
Beijing, China
Timeline & enrollment
Phase
Phase 2
Start date
Dec 01, 2021
End date
Jul 01, 2023
Enrollment
46 participants
Primary outcome

Binary reading of focal lesions identified on 68Ga-NY104 PET/CT

Summary

This is a prospective, single-center study in patients with renal cell carcinoma. The goal is
 to determine the sensitivity and specificity of 68Ga-NY104 PET/CT in the detection of clear
 cell renal cell carcinoma.

ICD-10 classifications
Malignant neoplasm of kidney, except renal pelvisMalignant neoplasm of renal pelvisSecondary malignant neoplasm of kidney and renal pelvisBenign neoplasm: KidneyBenign neoplasm: Renal pelvis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05902377
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05902377 through Pure Global AI's free database. This Phase 2 trial is sponsored by Peking Union Medical College Hospital and is currently Recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 46 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.